Bianchini Francesco, Aurigemma Cristina, Trani Carlo, Burzotta Francesco
Department of Cardiovascular and Pulmonary Sciences, Università Cattolica del Sacro Cuore, Rome, Italy.
Department of Cardiovascular Sciences, CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii36-iii39. doi: 10.1093/eurheartjsupp/suaf013. eCollection 2025 Mar.
Mitral regurgitation (MR) is the most common valvular disease in industrialized countries, with a significant impact on patient quality of life and survival, especially in an increasingly elderly and comorbid population. Repair surgery is considered the treatment of choice for primary MR, offering excellent long-term outcomes. However, the MitraClip system, a less invasive percutaneous option based on the edge-to-edge principle, has proved to be a valid alternative for patients at high surgical risk, showing initial benefits in terms of fewer post-operative complications. Surgery remains superior in terms of durability and prevention of residual regurgitation, but the MitraClip system offers advantages in selected patients, with improvements in quality of life and reductions in hospitalizations for heart failure. A multidisciplinary approach and careful patient selection are essential to optimize outcomes.
二尖瓣反流（MR）是工业化国家最常见的瓣膜疾病，对患者的生活质量和生存率有重大影响，尤其是在日益老龄化且合并多种疾病的人群中。修复手术被认为是原发性MR的首选治疗方法，可提供出色的长期疗效。然而，MitraClip系统是一种基于边对边原理的侵入性较小的经皮治疗选择，已被证明是高手术风险患者的有效替代方案，在减少术后并发症方面显示出初步益处。手术在耐久性和预防残余反流方面仍然更具优势，但MitraClip系统在特定患者中具有优势，可改善生活质量并减少因心力衰竭住院的次数。多学科方法和仔细的患者选择对于优化治疗效果至关重要。
